Financial Results : Almoosa Health’s Q1 2025 profit surges to SAR 51.1M

Almoosa Health’s Q1 2025 profit surges to SAR 51.1M

06/05/2025 Argaam Exclusive

View other reports

Almoosa Health Co. reported a net profit of SAR 51.1 million in Q1 2025, a more than three-fold increase from SAR 13.7 million in Q1 2024.



Current Quarter Comparison (M)

Compared With The
Item Q1 2024 Q1 2025 Change‬
Revenues 277.16 322.98 16.5 %
Gross Income 78.54 98.79 25.8 %
Operating Income 30.64 48.06 56.8 %
Net Income 13.73 51.13 272.5 %
Average Shares 35.00 44.30 26.6 %
Earnings Per Share before unusual items (Riyal) 0.39 1.13 187.1 %
EPS (Riyal) 0.39 1.15 194.3 %

Operational efficiency in managing costs contributed to this improvement, with lower financing costs due to a loan settlement in Q1.

 

Q1 revenue grew by 16.5% year-on-year (YoY) to SAR 323 million, driven by an increase in inpatient and outpatient volumes at Almoosa Specialist Hospital and expansion of specialty offerings.

 

Additionally, the significant increase in net income was primarily driven by revenue growth, which resulted from an increase in patients’ volume in addition to higher inpatient occupancy.

 

EBITDA grew by 38% in Q1 2025 to SAR 73.9 million, with margin expansion to 22.9% from 19.3% in Q1 2024.

 

On a sequential basis, net earnings dropped 5.4% from SAR 54.03 million in Q4 2024.

 

Total shareholders’ equity, no minority interest, stood at SAR 1.9 billion as of March 31, 2025, compared to SAR 642.8 million a year earlier.

Attached document 

 

 

 

View More Financial Results

 


Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 - - - - - -
Q2 2021 - - - - - -
Q3 2021 - - - - - -
Q4 2021 - - - - - -
Q1 2022 - - - - - -
Q2 2022 - - - - - -
Q3 2022 - - - - - -
Q4 2022 - - - - - -
Q1 2023 232.66 - 69.80 - 27.69 -
Q2 2023 230.46 - 68.31 - 27.44 -
Q3 2023 243.04 - 65.85 - 30.96 -
Q4 2023 272.81 - 103.03 - 27.92 -
Q1 2024 277.16 19.1 % 78.54 12.5 % 30.64 10.7 %
Q2 2024 284.59 23.5 % 75.17 10.0 % 20.90 (23.8 %)
Q3 2024 308.48 26.9 % 98.07 48.9 % 47.42 53.2 %
Q4 2024 332.11 21.7 % 119.95 16.4 % 69.69 149.6 %
Q1 2025 322.98 16.5 % 98.79 25.8 % 48.06 56.8 %


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS(Riyal)
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 - - - - - -
Q2 2021 - - - - - -
Q3 2021 - - - - - -
Q4 2021 - - - - - -
Q1 2022 - - - - - -
Q2 2022 - - - - - -
Q3 2022 - - - - - -
Q4 2022 - - - - - -
Q1 2023 26.09 - 0.75 - 26.09 0.75
Q2 2023 22.30 - 0.64 - 22.30 0.64
Q3 2023 29.57 - 0.84 - 29.57 0.84
Q4 2023 20.18 - 0.58 - 20.18 0.58
Q1 2024 13.73 (47.4 %) 0.39 - 13.73 0.39
Q2 2024 (1.26) (105.7 %) (0.04) - (1.26) (0.04)
Q3 2024 27.93 (5.6 %) 0.80 - 27.93 0.80
Q4 2024 54.03 167.7 % 1.54 - 54.03 1.54
Q1 2025 51.13 272.5 % 1.15 1.24 49.89 1.13

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 - - -
Q1 2023 - - -
Q2 2023 - - -
Q3 2023 - - -
Q4 2023 31.36 % - 10.03 %
Q1 2024 30.85 % - 8.38 %
Q2 2024 29.94 % - 5.77 %
Q3 2024 31.04 % 17.91 % 5.30 %
Q4 2024 30.92 % 20.96 % 7.85 %
2024 30.92 % 20.96 % 7.85 %
Q1 2025 31.40 % 21.77 % 10.46 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Earnings Per Share before unusual items (Riyal) Book Value (BV)
Q1 2016 - - - -
Q2 2016 - - - -
Q3 2016 - - - -
Q4 2016 - - - -
Q1 2017 - - - -
Q2 2017 - - - -
Q3 2017 - - - -
Q4 2017 - - - -
Q1 2018 - - - -
Q2 2018 - - - -
Q3 2018 - - - -
Q4 2018 - - - -
Q1 2019 - - - -
Q2 2019 - - - -
Q3 2019 - - - -
Q4 2019 - - - -
Q1 2020 - - - -
Q2 2020 - - - -
Q3 2020 - - - -
Q4 2020 - - - -
Q1 2021 - - - -
Q2 2021 - - - -
Q3 2021 - - - -
Q4 2021 - - - -
Q1 2022 - - - -
Q2 2022 - - - -
Q3 2022 - - - -
Q4 2022 - - - -
Q1 2023 35.00 - - 19.26
Q2 2023 35.00 - - -
Q3 2023 35.00 - - 20.83
Q4 2023 35.00 2.80 2.80 18.74
Q1 2024 35.00 2.45 2.45 18.37
Q2 2024 35.00 1.78 1.78 18.09
Q3 2024 35.00 1.73 1.73 18.91
Q4 2024 35.00 2.70 2.70 20.51
Q1 2025 44.30 2.98 2.95 43.12

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Recurring P/E Price/book
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 - - -
Q1 2023 - - -
Q2 2023 - - -
Q3 2023 - - -
Q4 2023 - - -
Q1 2024 - - -
Q2 2024 - - -
Q3 2024 - - -
Q4 2024 - - -
Q1 2025 50.47 50.95 3.48

Business Segments (Million)

Compared With The
Period medical services Pharmaceuticals Rehabilitation
Q1 2023 188.34 44.33 -
Q4 2023 200.95 56.36 15.50
Q1 2024 198.18 58.67 20.30
Q2 2024 172.08 70.77 41.74
Q4 2024 227.64 65.02 39.45
Q1 2025 214.15 74.30 34.53

Analysts Estimates (Million)

Item Profit (Expected) Profit (Actual) Change Profit Before Unusual Items Change
Average 34.30 51.13 49.89

Estimates vs Actual (Million)

Item Profit (Expected) Profit (Actual) Change‬ Profit Before Unusual Items Change‬
AlJazira Capital 34.30 51.13 49.89


Financial Ratios
Current
Market Cap (M Riyal) 7,300.65
Enterprise Value (EV) (M Riyal) 7,737.86
Shares Outstanding ((M)) 44.30
EPS ( Riyal) (TTM) 4.17
Book Value (BV) ( Riyal) 43.08
Par Value ( Riyal) 10.00
Recurring P/E 39.37
P/E (TTM) 39.49
Price/book 3.83
Return on Average Assets (%) (TTM) -
Return on Average Equity (%) (TTM) 14.5
EV/adj EBITDA 25.12
EV/Revenues 5.90
more

Share Price

Almoosa Health Co.
164.80
(1.60) (0.96 %)

Almoosa Health Co. (ALMOOSA)

More

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.